StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Novavax's price to sales ratio was 4.0× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.3× to 9.0×, with a median of 1.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20264.0×+2.9
2025Dec 31, 20251.0×−0.4
2024Dec 31, 20241.5×+0.9
2023Dec 29, 20230.5×+0.1
2022Dec 30, 20220.4×−8.5
2021Dec 31, 20219.0×−25.3
2020Dec 31, 202034.3×+27.9
2019Dec 31, 20196.4×−11.9
2018Dec 31, 201818.3×+3.6
2017Dec 29, 201714.7×−6.9
2016Dec 30, 201621.6×−39.4
2015Dec 31, 201561.0×+17.7
2014Dec 31, 201443.3×−5.1
2013Dec 31, 201348.4×+37.3
2012Dec 31, 201211.1×–

More Novavax figures

See a number that looks wrong?